A Phase III, Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Pegylated exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors PegBio
- 26 Jun 2023 Primary endpoint (Change in HbA1c) has been met according to results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2023 Status changed to completed according to results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2023 Results assessing Efficacy and Safety of Once-Weekly PB-119 Monotherapy vs. Placebo in Chinese Patients with Type 2 Diabetes presented at the 83rd Annual Scientific Sessions of the American Diabetes Association